Results 51 to 60 of about 3,177 (166)
Treatment of Solar Lentigines: A Systematic Review of Clinical Trials
Journal of Cosmetic Dermatology, Volume 24, Issue 4, April 2025.ABSTRACT Background Solar lentigines, resulting from chronic UV exposure, are early signs of photoaging and can significantly affect individuals. Aims This systematic review evaluates the efficacy, safety, and tolerability of treatments for solar lentigines in light of a lack of conclusive evidence regarding optimal therapy options.
Ghazal Mardani +4 more
wiley +1 more source
Melasma Management: A Comprehensive Review of Treatment Strategies Including BTX‐A
Journal of Cosmetic Dermatology, Volume 24, Issue 2, February 2025.ABSTRACT Background Botulinum toxin A (BTX‐A) is a widely utilized protein derived from the bacterium Clostridium botulinum, known for its effectiveness in treating various medical conditions involving muscle spasticity, involuntary muscle movements, and pain disorders.
Barbara Kania +2 more
wiley +1 more source
Journal of Cosmetic Dermatology, Volume 24, Issue 9, September 2025.
Rafael Rodrigo Crisanto de Oliveira
wiley +1 more source
Scleral melt following Retisert intravitreal fluocinolone implant
Drug Design, Development and Therapy, 2014 Ilias Georgalas,1 Chrysanthi Koutsandrea,1 Dimitrios Papaconstantinou,1 Dimitrios Mpouritis,1 Petros Petrou1,2 1Ophthalmology Department, University of Athens, Athens, Greece; 2Moorfields Eye Hospital, London, UKAbstract: Intravitreal fluocinolone ...
Georgalas I +4 more
doaj
Clinical Ophthalmology, 2020 Javier Zarranz-Ventura, 1, 2 Joshua O Mali 3 1Clinical Institute of Ophthalmology (ICOF), Hospital Clinic, Barcelona, Spain; 2August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; 3The Eye Associates, Sarasota, FL ...
Zarranz-Ventura J, Mali JO
doaj
Ophthalmology and Therapy, 2018 Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion ...
William Fusi-Rubiano +4 more
doaj +1 more source
Clinical Ophthalmology, 2018 Buraa Kubaisi,1,2 Arash Maleki,1,2 Aseef Ahmed,1,2 Neel Lamba,1,2 Haitham Sahawneh,1,2 Andrew Stephenson,1,2 Alyssa Montieth,1,2 Shobha Topgi,3 C Stephen Foster1,2,4 1Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA; 2Ocular ...
Kubaisi B +8 more
doaj
Update on corticosteroids for diabetic macular edema
Clinical Ophthalmology, 2016 Stephen G Schwartz,1 Ingrid U Scott,2,3 Michael W Stewart,4 Harry W Flynn Jr1 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 2Department of Ophthalmology, 3Department of Public Health
Schwartz SG +3 more
doaj
Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids
American Journal of Ophthalmology Case Reports, 2017 Purpose: To report the case of an adult male with X-linked retinoschisis (XLRS) who presented with cystoid macular edema (CME) that responded consistently to treatment with intravitreal steroids.
Waseem H. Ansari +2 more
doaj +1 more source
Fluocinolone Acetonide Ophthalmic ??? Bausch & Lomb
Drugs in R & D, 2005 Bausch & Lomb and Control Delivery Systems have developed an intravitreal implant that can deliver the corticosteroid fluocinolone acetonide [fluocinolone acetonide implant, Retisert] to posterior eye tissue for up to 3 years. The implant uses Bausch & Lomb's Envision TD technology.
openaire +2 more sources